Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
ATEC secures exclusive U.S. commercial rights to Theradaptive’s OsteoAdapt osteoinductive bone graft, currently in clinical trials for spinal and dental applications
The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
The FDA also noted that current prescribing information for GLP-1 RAs already includes warnings about the risk of suicidal thoughts
Experts caution that realizing AI’s potential requires careful management and risk mitigation
Subscribe To Our Newsletter & Stay Updated
